Accelr8 Technology Corporation (NYSE Mkt: AXK), a developer of automated diagnostic systems for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens, announced today that Dr. Matthew Strobeck has been appointed to Accelr8's Board of Directors.
Dr. Strobeck has extensive experience in the global pharmaceuticals and diagnostics industries. Most recently Dr. Strobeck was a Partner, Member of the Management Committee and Member of the Advisory Board of Westfield Capital Management, an investment firm with approximately $15 billion in assets under management. Dr. Strobeck organized and completed the repurchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the investment team (since 2004). Dr. Strobeck currently serves as a Director of Biodesix and previously served on the boards of Metabolix Inc., Collegium Pharmaceuticals and Precision Dermatology. Dr. Strobeck received a B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.
"We are delighted to have Dr. Strobeck join our Board. In addition to his extensive experience as a healthcare analyst, Matt’s knowledge of the global diagnostics industry, specifically as it relates to our field, will be invaluable as Accelr8 grows its microbiology franchise," commented John Patience, Accelr8’s Chairman.
About Accelr8Accelr8 Technology Corporation ( www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products. Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.